A Swallowable Auto-Injector Capsule That Delivers Insulin, GLP-1, and Antibodies Through Your Stomach

Researchers designed an orally administered liquid auto-injector capsule and tested it in swine (pigs), which have gastrointestinal anatomy similar to humans. They measured bioavailability, pharmacokinetics (how quickly drugs reached peak blood levels), and dosing consistency across multiple days. Four clinically relevant injectable medications were tested: adalimumab, a GLP-1 analog, recombinant human insulin, and epinephrine. Both sedated and awake animal models were used.

Millions of people inject peptide drugs daily or weekly — insulin for diabetes, GLP-1 agonists for obesity, adalimumab for autoimmune conditions. Needle fear, injection burden, and the need for cold-chain storage are major barriers to treatment adherence. A capsule that achieves injection-like bioavailability could transform how these drugs are delivered, making treatment simpler and more accessible for patients worldwide.

This research represents a potential paradigm shift in peptide drug delivery. While oral semaglutide (Rybelsus) exists, it achieves only about 1% bioavailability using chemical absorption enhancers. This mechanical approach — physically injecting the drug through the stomach lining — achieves 80% bioavailability, which is orders of magnitude better. Published in Nature Biotechnology by researchers from MIT and Novo Nordisk, this technology could eventually make oral delivery feasible for virtually any injectable peptide or biologic.

All experiments were conducted in pigs, not humans. While swine GI anatomy is similar to humans, translation to clinical use requires human safety and efficacy trials. The long-term safety of repeated stomach wall injections is unknown. The capsule's size, manufacturing scalability, and cost are not discussed. Patient acceptability of swallowing an auto-injecting capsule has not been studied.